Free Trial

Cue Biopharma Q1 2024 Earnings Report

Cue Biopharma logo
$0.79 -0.12 (-13.28%)
As of 02:11 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cue Biopharma EPS Results

Actual EPS
-$0.25
Consensus EPS
-$0.30
Beat/Miss
Beat by +$0.05
One Year Ago EPS
N/A

Cue Biopharma Revenue Results

Actual Revenue
$1.72 million
Expected Revenue
$0.73 million
Beat/Miss
Beat by +$990.00 thousand
YoY Revenue Growth
N/A

Cue Biopharma Announcement Details

Quarter
Q1 2024
Time
N/A
Remove Ads

Cue Biopharma Earnings Headlines

Partner with Elon Musk on Project Colossus… Before May 1st
Even though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.
Artiva expands Board with appointment of Dan Baker, M.D
See More Cue Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cue Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cue Biopharma and other key companies, straight to your email.

About Cue Biopharma

Cue Biopharma (NASDAQ:CUE), a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

View Cue Biopharma Profile

More Earnings Resources from MarketBeat